KYNTRA BIO, INC.(KYNB)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

KYNTRA BIO, INC. (KYNB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KYNB at 41.6/100 on a 32-signal composite quality model, placing it at rank #2,051 of 2,960 stocks — the bottom half of the AI-ranked universe. KYNB scores in the top quartile across profitability (100.0), balance sheet strength (100.0). Areas of concern include revenue scale (1.2) and free cash flow (2.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), KYNTRA BIO, INC. reports quarterly revenue of $-1.5M, net income of $12.0M, free cash flow of $-4.0M. Top institutional holders of KYNB by reported 13-F value include ARMISTICE CAPITAL, VANGUARD CAPITAL MANAGEMENT, ACADIAN ASSET MANAGEMENT, based on the most recent SEC filings. KYNB trades on the Nasdaq exchange and files with the SEC under CIK 921299. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KYNB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KYNTRA BIO, INC. directly from SEC EDGAR.